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Edited by Beat ImhofAbstract Platelet-activating factor (PAF) augments angiogen-
esis by promoting the synthesis of various angiogenic factors,
via the activation of NF-jB. In this study, we investigated the
role of the matrix metalloproteinase (MMP)-9, in PAF-induced
angiogenesis. PAF increased mRNA expression, protein synthe-
sis, and MMP-9 activity in ECV304 cells, in a NF-jB-dependent
manner. PAF increased MMP-9 promoter activity in ECV304,
which was inhibited by WEB2107, and NF-jB inhibitors. Trans-
fected NF-jB subunits, p65 or/and p50, increased luciferase
activity in the reporter plasmid MMP-9, resulting in an increase
not only of MMP-9 luciferase activity, but also of mRNA
expression in MMP-9. MMP-9 or NF-jB inhibitors signiﬁ-
cantly inhibited PAF-induced angiogenesis, in a dose-dependent
manner, in an in vivo mouse Matrigel implantation model. In a
parallel to the Matrigel implantation study, MMP-9 or NF-jB
inhibitors inhibited PAF-induced sprouting of porcine pulmonary
arterial endothelial cells. These data indicate that NF-jB-depen-
dent MMP-9 plays a key role in PAF-induced angiogenesis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The proteolytic degradation of extracellular matrix (ECM)
components is involved in both physiological and pathological
processes, such as development, tissue remodeling, inﬂamma-
tion, tumor cell invasion, and tumor metastasis. ECM
degradation is especially associated with the matrix metallo-
proteinases (MMPs), which are a family of zinc-dependent
endopeptidases [1]. MMPs constitute a multigene family of
at least 26 secreted and membrane-tethered endopeptidases,
which can be classiﬁed according to their structures andAbbreviations: MMP, matrix metalloproteinase; PAF, platelet-activat-
ing factor; p65 AS, p65 antisense oligonucleotide; p65 NS, p65 non-
sense scrambled oligonucleotide; PPAEC, porcine pulmonary arterial
endothelial cell
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collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9),
stromelysins (MMP-3, -7, -10, -11, -12), and membrane-type
(MT)-MMPs (MT1-MMP to MT6-MMP). MMP-2 (gelatin-
ase A) and MMP-9 (gelatinase B) constitute a distinct sub-
group of the MMP family, due to the incorporation of three
repeats of the ﬁbronectin-type II module in the catalytic do-
main. These enzymes have been shown to play a key role in tu-
mor cell invasion, metastasis, and angiogenesis, by promoting
ECM degradation and the processing of cytokines, growth fac-
tors, hormones, and cell receptors [4,5].
Platelet-activating factor (PAF), which is produced by a
variety of inﬂammatory cells, is a potent lipid mediator in-
volved in cellular activation, fertilization, intracellular signal-
ing, apoptosis, and a myriad of inﬂammatory reactions [6–
10]. We have previously demonstrated that PAF is a proximal
inducer of the transcription factor, NF-jB, a key component
necessary for the expression of proinﬂammatory cytokines
and many immunoregulatory molecules [11,12] in response
to inﬂammatory stimuli [13,14] and microbial infection [15].
PAF also augments angiogenesis by promoting various angio-
genic factors via activation of NF-jB [16]. As NF-jB activity
has been associated with the regulation of protein levels of
MMP-9 [17,18], but not MMP-2 [19], NF-jB-dependent
MMP-9 may play a role in PAF-induced angiogenesis.
In this study, we investigated the possibility and found that
MMP-9, the expression of which is regulated by NF-jB activa-
tion, plays a key role in PAF-induced angiogenesis.2. Materials and methods
2.1. Animals
Speciﬁc pathogen-free female BALB/c mice were obtained from the
Korean Institute of Chemistry Technology (Daejeon, Korea) and were
kept in our animal facility for at least 2 weeks before use. All mice were
used at 8–10 weeks of age.2.2. Reagents
PAF (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) was pur-
chased from Sigma Chemical Co. (St. Louis, MO). The PAF receptor
antagonist, WEB2170, was a gift from Dr. C.K. Rhee (College of Med-
icine, Dankook University, Korea). The NF-jB inhibitor, partheno-
lide, was purchased from BIOMOL Research Laboratories Inc.
(Plymouth Meeting, PA), and another NF-jB inhibitor, PDTC, andblished by Elsevier B.V. All rights reserved.
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Matrigel, an extract of murine basement membrane proteins, consist-
ing predominantly of laminin, collagen IV, heparin sulfate proteogly-
cans, and nidogen/entactin, was purchased from Collaborative
Research Inc. (Bedford, MA). Neutralizing antibody against MMP-9
was from Chemicon International (Temecula, CA). For immunohisto-
logical staining, antibodies used included anti-von Willebrand Factor
(vWF) (DakoCytomation, Glostrup, Denmark), and anti-Ulex euro-
peaus agglutinin-1 (UEA-1) (Sigma).
2.3. Antisense oligonucleotides
The following phosphorothioate oligonucleotides were synthesized
for use in antisense inhibition of gene expression (Peptron, Korea):
p65 AS of the 5 0 end of the NF-jB gene (5 0-GAAACAGATCGTC-
CATGGT-3 0) and p65 NS (5 0-GTACTACTCTGAGCAAGGA-3 0).
The AS and NS oligonucleotides include the ATG initiation codon.
2.4. Cell culture
ECV304 cells, an immortalized and transformed human vascular
endothelial cell line [20], and PPAEC were prepared by collagenase
digestion as described [21] were maintained in Dulbeccos modiﬁed
Eagle medium (DMEM, GIBCO, Island, NY) supplemented with
10% (v/v) fetal bovine serum (CAMBREX Co., Walkersville, MD)
at 37 C in a 5% CO2 atmosphere. Porcine pulmonary arterial endothe-
lial cells (PPAEC) used in the sprouting assay were between passages 2
and 4. Human ﬁbrosarcoma cell line, HT-1080 was maintained in Min-
imum Essential Medium (MEM, GIBCO) supplemented with 10%
(v/v) fetal bovine serum (CAMBREX).
2.5. Real-time RT-PCR
RNA was prepared as previously described [13,14]. Reverse tran-
scription was performed using 0.1 lg of total RNA in a 10 ll reaction
mixture (Promega, Madison, WI), containing oligo(dT) and avian
myeloblastosis virus reverse transcriptase. PCR was performed on
the Roter-Gene 3000 System (Corbett Research, Morklake, Australia)
using the SYBR Green PCR Master Mix Reagent Kit (Qiagen, Valen-
cia, CA). The primers used are as follows: MMP-9 for real-time PCR,
5 0-TGACAGCGACAAGAAGTG-3 0 and 5 0-CAGTGAAGCGGT-
ACATAGG-3 0; MMP-9 for the visualization of the results,
5 0-ATCCAGTTTGGTGTCGCGGAGC-3 0 and 5 0-GAAGGGGAA-
GACGCACAGCT-3 0; b-actin, 5 0-CTGAAGTCACCCATTGAA-
CATGGC-30 and 5 0-CAGAGCAGTAATCTCCTTCTGCA-3 0. The
relative levels of mRNA of MMP-9 were calculated using the standard
curve generated from cDNA dilutions. The mean cycle threshold (Ct)
values from quadruplicate measurements were used to calculate the
gene expression, with normalization to b-actin as an internal control.
Calculations of the relative level of gene expression were conducted
according to the complementary computer software (Corbett Re-
search) using standard curve. cDNA, ampliﬁed by PCR (Perkin–Elmer
System 2400, Norwalk, CT), was visualized after staining with ethi-
dium bromide.
2.6. Electrophoretic mobility shift assay
Nuclear extracts were prepared from the cells, as previously de-
scribed [13,14]. To inhibit endogenous protease activity, 1 mM phenyl-
methylsulfonyl ﬂuoride was added. As a probe for the gel retardation
assay, an oligonucleotide containing the Igj-chain binding site (jB,
5 0-CCGGTTAACAGAGGGGGCTTTCCGAG-3 0) was synthesized.
The two complementary strands were annealed, and labeled with
[a-32P]dCTP. Labeled oligonucleotides (10000 cpm), 12 lg of nuclear
extracts, and binding buﬀer [10 mM Tris–HCl, pH 7.6, 500 mM
KCl, 10 mM EDTA, 50% glycerol, 100 ng of poly(dIdC), and 1 mM
DTT] were incubated for 30 min at room temperature in a ﬁnal volume
of 20 ll. The reaction mixture was analyzed by electrophoresis on a 5%
polyacrylamide gel in 0.5· Tris-borate buﬀer. Speciﬁc binding was con-
trolled by competition with a 50-fold excess of cold jB or cAMP re-
sponse element (CRE) oligonucleotide.
2.7. Western blot analysis
Cells (1 · 106/60 mm dish) were seeded in complete medium and cul-
tured for 6 h for purposes of anchorage. The cells were washed with
serum-free medium twice, and grown in serum-free medium overnight,
then treated with 1.8 lM of PAF for 24 h. Equal amounts of superna-tants were separated onto 10% SDS polyacrylamide gel under reducing
conditions, and then transferred onto Protran nitrocellulose mem-
branes (Schleicher & Schuell, NH). Equal protein loading was veriﬁed
by both staining the gel and the membrane with Coomassie brilliant
blue R-250 and Ponceau S (Sigma), respectively. The membranes were
blocked for 1 h at room temperature in 3% BSA in PBS, followed by
2 h of incubation with anti-MMP-9 antibody (Oncogene Research
Products, San Diego, CA) which recognizes only the latent form under
reducing conditions. Blots were washed for 15 min with three changes
of PBS-0.05% Tween 20 solution, followed by 1 h of incubation at
room temperature with HRP-conjugated anti-rabbit IgG antibody
(Santa Cruz Biotechnology Inc., CA). The blots were washed again
for 15 min, and ﬁnally detected by NBT/BCIP (Promega, Madison,
WI).
2.8. Zymography
To assess collagenase activity, the supernatant was collected and
concentrated 30-fold using an Amicon Centricon (Millipore Co., Bed-
ford, MA, USA). The samples were electrophoretically separated onto
8.5% SDS–polyacrylamide gel containing 1 mg/ml of gelatin (Sigma).
After electrophoresis, the gel was washed at room temperature for
1 h in wash buﬀer (50 mM Tris–Cl, pH 7.4, 2.5% Triton X-100) and
incubated at 37 C overnight in incubation buﬀer (50 mM Tris–Cl,
pH 7.4, 75 mM NaCl, and 2.5 mM CaCl2). The gel was stained with
0.2% Coomassie brilliant blue R-250 in a mixture of methanol:acetic
acid:water (2:1:7) for 2 h, and then destained in the same solution,
without dye. Clear zones against the blue background indicated the
presence of gelatinolytic activity. The supernatant of the HT1080 cells
was used as a reference standard for proMMP-9.
2.9. Transient expression assay
The HindIII–KpnI fragment comprising 1285 to 20 bp of the
MMP-9 promoter (pGL3-M9Pwt, a kind gift from Dr. S-T Lee, Yon-
sei University, Korea) was cloned upstream of the promoterless lucif-
erase reporter vector in the pGL3-Basic. cDNA encoding p65, p50,
IjBa were cloned in pcDNA3. Plasmid DNA was prepared using com-
mercial kits (Qiagen, Chatsworth, CA). ECV304 cells were cultured to
60–80% conﬂuence in 24-well plates. 0.8 lg of plasmid DNA and 1 ll
of LipofectAMINE reagent (Life Technologies, Inc., Gaithersburg,
MD) were separately diluted in 50 ll of Opti-MEM reduced serum
medium (Life Technologies, Inc.), mixed together, and incubated at
room temperature for 1 h. Plates were then washed with serum-free
medium, 200 ll of Opti-MEM reduced serum medium was added,
and the diluted solution was added to the cells. Plates were then incu-
bated at 37 C for 8 h, after which time growth medium containing
10% serum was added, and cells were maintained for an additional
16 h. Cells were then either left untreated, or were treated with
1.8 lM of PAF for 8 h. Cell extracts were prepared using passive lysis
buﬀer (Promega, Madison, WI). Luciferase assays were carried out
using the Lumat LB9501 luminometer (Berthold, Germany). All exper-
iments were repeated at least three times, with two diﬀerent batches of
puriﬁed DNA.
2.10. Angiogenesis assay
In the angiogenesis assay, angiogenesis was considered to be indi-
cated by the growth of blood vessels from subcutaneous tissue into a
solid gel of basement membrane containing the test sample, as previ-
ously described [16]. Brieﬂy, Matrigel (10 mg/ml, in liquid form at
4 C) was mixed with 64 U/ml of heparin and the experimental sub-
stances or vehicle alone, and injected (0.5 ml) into the dorsal subcuta-
neous tissues of the mice. After 14 days, the mice were killed, and the
gels were recovered and processed for the determination of angiogen-
esis. The degree of angiogenesis was estimated by measuring hemoglo-
bin (Hb) contents in Matrigel, using the Drabkin reagent kit 525
(Sigma). Results were expressed as mg Hb/dl.2.11. Immunohistochemistry
To determine angiogenesis in the Matrigel plug, we performed
immunohistochemical detection of the von Willebrand factor (vWF),
which is used widely as a marker of neovascularization. The Matrigels
were ﬁxed in 4% paraformaldehyde (Sigma) overnight at 4 C. The
Matrigels were then washed in PBS, dehydrated in a graded series of
ethanol washes, and embedded in paraﬃn. Immunoperoxidase staining
Fig. 1. PAF induces the mRNA expression and gelatinolytic activity
of MMP-9. ECV304 cells (1 · 106) were treated with 1 or 10 lg/ml of
WEB2170, 30 min prior to PAF treatment (1.8 lM). (A,B) For the
detection of MMP-9 mRNA expression and protein synthesis, real-
time RT-PCR and Western blot analysis were performed, as described
in Section 2. The results of agarose gel electrophoresis of RT-PCR are
shown (inset), as are the combined quantitative analysis results by real-
time RT-PCR. (C) For detection of gelatinolytic activity, zymography
was performed. Conditioned media were collected after 24 h, and
aliquots corresponding to equal amounts of cells were subjected to
gelatin zymography. The positions of MMP-9 are indicated. Condi-
tioned media of the HT1080 cells was loaded as a standard for pro
MMP-9 (HT). \P < 0.0001 compared with control group; \\P < 0.0001
compared with PAF-treated group. Values are expressed as
means ± S.E.
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(ZYMED Lab. Inc., San Francisco, CA), according to manufacturers
recommendations. In brief, serial sections of paraﬃn-embedded Matri-
gel were deparaﬃnized in xylene, rehydrated in graded series of etha-
nol, rinsed twice in PBS, and then treated with 3% H2O2 in
methanol for 30 min to reduce endogenous peroxidase activity. The
sections were then incubated with serum block solution for 30 min, fol-
lowed by incubation with diluted primary antibody for 1 h and were
rinsed three times in PBS. The specimens were incubated with corre-
sponding biotinylated secondary antibodies for 10 min and then
HRP–streptavidin complex for 10 min. Color was developed for
3 min using HRP substrate, and then the samples were counterstained
with hematoxylin. Finally, the sections were examined and photo-
graphed.
2.12. Endothelial sprouting assay
To investigate the eﬀects of PAF on angiogenesis in vitro, endothe-
lial sprouting was assessed, as previously described [21]. Brieﬂy, micro-
carrier beads coated with denatured collagen (Cytodex 3; Sigma) were
seeded with PPAEC and embedded in ﬁbrin gels in 24-well plates. For
preparation the ﬁbrin gels, bovine ﬁbrinogen (6 mg/ml) and aprotinin
(32 U/ml) were dissolved in PBS. The ﬁbrinogen solution was supple-
mented with PAF and inhibitors. As a control, the ﬁbrinogen solution
was supplemented with PBS. The ﬁbrinogen solutions were transferred
to 24-well plates together with PPAEC-coated beads at a density of 150
beads/well. Clotting was induced by the addition of thrombin (25 U/
ml). After clotting was complete, gels were equilibrated with DMEM
containing 2% FBS with or without various treatments at 37 C. After
3 days of incubation with daily changes of the medium, the number of
capillary-like tubes formed per microcarrier bead (sprouts/bead) was
counted by microscopy, monitoring at least 450 beads for each treat-
ment. Only sprouts greater than the bead diameter in length and com-
posed of at least three endothelial cells were counted.
2.13. Statistical analysis
Data are represented as means ± S.E. Statistical signiﬁcance was
determined by the Students t test when two data sets were analyzed
or, alternatively, by ANOVA followed by the appropriate post-hoc test
for multiple data sets with the statistical software StatView (version
4.5). All experiments were conducted two or more times. Reproducible
results were obtained and representative data are therefore shown in
the ﬁgures.3. Results
3.1. PAF -induced NF-jB-dependency of the expression of
mRNA and activity of MMP-9
We ﬁrst performed immunohistochemistry using antibodies
against endothelial-speciﬁc antigens, vWF and UEA-1, in HU-
VECs and ECV304 cells to clarify that ECV304 cell line is of
endothelial origin. In ECV304 cells, faint positivity was de-
tected for vWF, but strong staining was exhibited in HUVECs,
and both were positive for UEA-1. Morphologically, both
ECV304 cells and HUVECs grew as cobblestone monolayers
composed of polygonal cells on plastic or gelatin-coated sur-
faces (data not shown). These ﬁndings were similar to those re-
ported by Hughess [22].
We attempted to examine whether PAF is able to express
MMP-9 through NF-jB activation in vitro. PAF induced in-
creases in the mRNA expression (Fig. 1A), protein synthesis
(Fig. 1B) and activities (Fig. 1C) of MMP-9 in ECV304 cells.
Pretreatment of the cells with PAF resulted in the activation
of NF-jB in the cells, peaking 1 h. This increased activation
was inhibited by WEB2170 (Fig. 2A) or p65 antisense oligonu-
cleotide (p65 AS) (Fig. 2B). Both p65 AS and parthenolide
inhibited the PAF-induced increases in mRNA expression
(Fig. 2C) and activities of MMP-9 (Fig. 2D), but p65 nonsenseoligonucleotide (scrambled control, p65 NS) was not found to
exert this inhibitory eﬀect. Furthermore, PAF enhanced
MMP-9 promoter activation in ECV304 cells, and that eﬀect
was completely inhibited by WEB2170 or NF-jB inhibitor,
parthenolide, and PDTC (Fig. 3A). Luciferase activity in-
creased in cells cotransfected with plasmids expressing p65
and/or p50 subunits of NF-jB (Fig. 3B). In a manner parallel
to the MMP-9 luciferase activity, MMP-9 mRNA expression
was increased by NF-jB subunits (Fig. 3C). Cotransfection
with IjBa, however, resulted in the reduction of luciferase
activity and MMP-9 mRNA expression back to basal levels
(Figs. 3B and C). Taken together, these data clearly indicate
that PAF enhances MMP-9 expression through NF-jB activa-
tion.
As shown in Figs. 1–3, PAF increased mRNA, protein, and
promoter activity of MMP-9. Another interesting ﬁnding is
that addition of PAF resulted in the conversion of proMMP-
9 to active form. Taken together, present results suggest that
PAF induces not only MMP-9 expression in the transcrip-
tional level, but also the proteolytic activation of proMMP-9.
3.2. Role of MMP-9 in PAF-induced angiogenesis
We determined the in vivo eﬀects of MMP-9 on PAF-in-
duced angiogenesis, using a murine model in which Matrigel
Fig. 2. PAF induces MMP-9 expression in a NF-jB-dependent manner. ECV304 cells (1 · 106) were treated with WEB2170 (1 lg/ml), or
parthenolide (1 lM), 30 min prior to PAF treatment (1.8 lM). 1 · 105 cells were treated with p65 AS (0.1 or 1 lM) or p65 NS oligonucleotide (1 lM),
3 days prior to PAF treatment. (A,B) Nuclear extracts were prepared 1 h after PAF treatment, incubated with a-32P-labeled jB or CRE
oligonucleotide, and electrophoresed on a 5% polyacrylamide gel. Real-time RT-PCR (C) and zymography (D) were performed as described in
Fig. 1. \P < 0.0001 compared with control group; \\P < 0.0001 compared with PAF-treated group. Values are expressed as means ± S.E.
Fig. 3. PAF or NF-jB activation increases MMP-9 promoter activity. (A) ECV304cells were plated at 3 · 104/24-well plate, transfected with 0.1 lg
of MMP-9 luciferase reporter plasmid. Cells were treated for 8 h with 1.8 lM of PAF. The PAF antagonist, WEB2170 (1 lg/ml), or the NF-jB
inhibitors, parthenolide (1 lM) and PDTC (10 lM), were added 30 min prior to PAF treatment. (B,C) Cells were cotransfected with MMP-9 reporter
plasmid (0.1 lg) and NF-jB subunits (0.2 lg of p65 and 0.1 lg of p50) and/or IjBa expression vector (0.2 or 0.4 lg). The total concentration of DNA
was adjusted to 0.8 lg per transfection with an empty vector. Luciferase activity was normalized by b-galactosidase activity, in order to determine
transfection eﬃciency. All promoter activities are shown as fold activation relative to control. (C) RNA was isolated 6 h after PAF treatment. Data
shown represent the mean of three independent experiments. \P < 0.0001 compared with control group; \\P < 0.0001 compared with PAF-treated
group; \\\P < 0.0001 compared with p65/p50-trasfected group. Values are expressed as means ± S.E.
2372 H.-M. Ko et al. / FEBS Letters 579 (2005) 2369–2375was injected s.c. The angiogenic activity of PAF was evaluated
using an in vivo mouse Matrigel implantation model. PAF
caused pronounced angiogenic activity and the MMP inhibi-
tor, 1,10-phenanthroline, signiﬁcantly inhibited PAF-induced
angiogenesis in a dose-dependent manner in vivo (Fig. 4A).
Immunohistochemistry was also used to assess the angiogenic
activity of MMP-9. Sections of Matrigel were immunostained
with rabbit anti-vWF antibody. A signiﬁcant number of eryth-
rocyte-containing canalized microvessels and vWF-positive
endothelial cells were observed within the Matrigel in PAF-
treated mice (Fig. 4Bb), but not in the Matrigel of the control(Fig. 4Ba) or PAF antagonist-treated groups (Fig. 4Bc). NF-
jB inhibitor (Fig. 4Bd) or MMP inhibitors (Fig. 4Be and Bf)
signiﬁcantly inhibited PAF-induced increases in the number
of vWF-positive endothelial cells and vessels. The results indi-
cate that MMP-9 plays an important role in PAF-induced
angiogenesis.
3.3. Role of MMP-9 in PAF-induced sprouts formation
We determined the in vitro eﬀect of MMP-9 on the PAF-in-
duced sprouting of PPAEC, given that the sprouting of the
endothelial cell is the initial step in angiogenesis, requiring cell
Fig. 4. MMP inhibitors block PAF-induced angiogenesis in vivo. (A) Matrigel containing 64 U/ml heparin was mixed with PAF (1 lg/plug) in the
presence or absence of WEB2170, and the NF-jB inhibitor, parthenolide, the MMP-9 inhibitor, 1,10-phenanthroline, or MMP-9 neutralizing
antibody. Isotype-matched mouse IgG was used as a negative control. Matrigel plugs were excised and processed for quantiﬁcation of angiogenesis
by measuring the Hb content on day 14. (B) Immunoperoxidase staining of Matrigel plugs was performed using anti-vWF antibody. Matrigel was
mixed with vehicle (Ba), PAF (Bb), PAF plus 10 lg of WEB2170 (Bc), PAF plus 5 lM of parthenolide (Bd), PAF plus 0.5 lM of 1,10-phenanthroline
(Be), PAF plus 10 lg of anti-MMP-9 (Bf). Arrows show examples of the erythrocyte-containing microvessels and staining of vWF. All magniﬁcations
are 400·. \P < 0.0001 compared with control group; \\P < 0.0001 compared with PAF-treated group. Values are expressed as means ± S.E.
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membrane [21,23]. Addition of PAF into PPAEC grown on
microcarrier beads in ﬁbrin gel resulted in increases in sprout
formation (Fig. 5A and Bb), an eﬀect which was inhibited by
the PAF antagonist, WEB2170 (Fig. 5A and Bc). As a positive
control, VEGF increased sprout formation in a dose-depen-
dent manner (Fig. 5A and Bf). Addition of NF-jB inhibitors
or MMP inhibitors signiﬁcantly inhibited the sprout forming
activity of PAF (Fig. 5A, Bd, and Be). The sprouting activity
of PAF was not due to proliferation of PPAEC because PAF
could not induce PPAEC proliferation in [3H]thymidine incor-
poration assay (data not shown). These data further support
the notion that NF-jB-dependent MMP-9 plays a key role
in PAF-induced angiogenesis.Fig. 5. NF-jB inhibitor or MMP inhibitor blocks PAF-induced
sprout formation. (A) Fibrin gels containing PPAEC-coated beads
were treated with PAF (1.8 lM) in the presence or absence of
WEB2170 (1 or 10 lg/ml), parthenolide (0.1 or 0.5 lM) or 1,10-
phenanthroline (0.1 or 0.5 lM), or recombinant VEGF (5, 10 ng/ml)
only. Sprout formation was determined by the means described in
Section 2. (B) Microscopic comparison of sprouting activities was
performed. Beads treated with vehicle (Ba), PAF (Bb) or 10 ng/ml of
VEGF (Bf). Beads treated with PAF plus 1 lg/ml of WEB2170 (Bc), or
0.5 lM of parthenolide (Bd), or 0.5 lM of 1,10-phenanthroline (Be).
The results were expressed as the number of capillary-like tubes
formed/50 beads. \P < 0.0001 compared with control group;
\\P < 0.0001 compared with PAF-treated group. Values are expressed
as means ± S.E.4. Discussion
Recent studies have demonstrated that PAF has the ability
to enhance tumor metastasis [24], and to induce in vitro migra-
tion of human endothelial cells. PAF is also known to promote
in vivo [25], and has been implicated as a mediator of angio-
genesis induced by angiogenic factors, such as TNF-a [26]
and hepatocyte growth factor [27]. Furthermore, it has been
suggested that PAF plays a role in neoangiogenesis observed
in tumors [28–30] and chronic inﬂammatory diseases such as
rheumatoid arthritis [31]. Regarding the mechanisms underly-
ing PAF-induced angiogenesis, we have recently shown that
PAF promotes angiogenesis through the activation of NF-
jB, which, in turn, promotes various angiogenic factors such
as IL-1, TNF-a, bFGF, and VEGF [16]. In this study, we dem-
onstrated that (1) PAF increased mRNA expression, protein
synthesis, and activity of MMP-9 in ECV 304 cells via the acti-
vation of NF-jB (Figs. 1–3), (2) MMP inhibitors inhibited
PAF-induced angiogenesis, evaluated by means of Matrigel
implantation (Fig. 4) and sprouting assay (Fig. 5), indicating
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pathway is an important eﬀector molecule in PAF-induced
angiogenesis, as evaluated by means of Matrigel and sprouting
assay.
Although MMP-9 is produced by various inﬂammatory
cells, little is known about the relationship between PAF
and MMP-9. Okada et al. [32] recently demonstrated that
eosinophils migrate through basement membranes by releas-
ing and activating MMP-9, and by degrading basement
membrane barriers when they are activated by PAF and
IL-5. Tao et al. [33] and Shan et al. [34] reported, respec-
tively, that PAF is able to induce MMP-9 expression in
the corneal epithelium and human bronchial epithelial cells.
Recently, It has been reported that PAF induces activation
of MMP-2 and vascular cell invasion and migration but
not the expression of MMP-9 in HUVECs [35]. However,
we could ﬁnd that PAF induces MMP-9 expression and
activity in the transcriptional level in ECV304 cells.
ECV304 cells have undergone spontaneous transformation
and immortalization by as yet undeﬁned mechanisms [20].
Furthermore, the results of in vitro angiogenesis assays using
primary endothelial cells from diﬀerent vascular beds as well
as either HUVEC isolates from diﬀerent cords or serially
passaged HUVECs were extremely variable [22]. In addition,
several functional responses have been either enhanced (in vi-
tro angiogenesis) or reduced (E-selectin) in ECV304 cells and
HUVECs [22]. These morphological as well as functional dif-
ferences may attribute to discordance of MMP-9 expression
between HUVECs and ECV304 cell line.
MMP-9 plays a critical role in the degradation of the base-
ment membrane, a structure which is composed largely of type
IV collagen, and separates the epithelial and stromal compart-
ments. Thus, MMP-9 activation can clearly result in tumor cell
invasion and metastasis [4,5]. In this study, anti-MMP-9 neu-
tralizing antibody inhibited PAF-induced angiogenesis almost
completely. These ﬁndings tell us that, given that anti-VEGF
neutralizing antibody also almost completely inhibited PAF-
induced angiogenesis [16], the MMP-9-induced degradation
of the basement membrane is as important as any of the other
potent factors in angiogenesis. Our unpublished data shows
that anti-MMP-9 neutralizing antibody and MMP inhibitor
signiﬁcantly inhibit the PAF-induced exacerbation of pulmon-
ary metastasis of murine melanoma tumor cells. This indicates
that MMP-9 is also involved in PAF-induced tumor
metastasis.
In conclusion, the ﬁndings of this study demonstrate that
PAF can enhance MMP-9 expression in a NF-jB-dependent
manner, and also that MMP-9 is one of the key regulators in
PAF-induced angiogenesis. This study will provide some in-
sight into PAF-induced angiogenesis, and also makes it clear
that targeting MMP-9 might be of great value in controlling
physiopathological angiogenesis.Acknowledgement: This work was supported by Korea Research Foun-
dation Grant KRF-2002-075-C00016 to H.-M. Ko. The ﬁrst two
authors contributed equally to this work.References
[1] Woessner Jr., J.F. (2002) MMPs and TIMPs: an historical
perspective. Mol. Biotechnol. 22, 33–49.[2] Massova, I., Kotra, L.P., Fridman, R. and Mobashery, S. (1998)
Matrix metalloproteinases: structures, evolution, and diversiﬁca-
tion. FASEB J. 12, 1075–1095.
[3] Nagase, H. and Woessner Jr., J.F. (1999) Matrix metalloprotein-
ase. J. Biol. Chem. 274, 21491–21494.
[4] Moses, M.A. (1997) The regulation of neovascularization of
matrix metalloproteinases and their inhibitors. Stem Cells 15,
180–190.
[5] Nguyen, M., Arkell, J. and Jackson, C.J. (2001) Human endo-
thelial gelatinases and angiogenesis. Int. J. Biochem. Cell Biol. 33,
960–970.
[6] Gay, J.C. (1993) Mechanism and regulation of neutrophil priming
by platelet-activating factor. J. Cell. Physiol. 156, 189–197.
[7] Fukuda, A.I. and Breuel, K.F. (1996) Eﬀect of platelet-activating
factor on embryonic development and implantation in the mouse.
Hum. Reprod. 11, 2746–2749.
[8] Shukla, S.D. (1992) Platelet-activating factor receptor and signal
transduction mechanisms. FASEB J. 6, 2296–2301.
[9] Buttke, T.M. and Sandstrom, P.A. (1995) Redox regulation of
programmed cell death in lymphocytes. Free Radic. Res. 22, 389–
397.
[10] Braquet, P., Touqui, L., Shen, T.Y. and Vargaftig, B.B. (1987)
Perspectives in platelet-activating factor research. Pharmacol.
Rev. 39, 97–145.
[11] Baeuerle, P.A. and Baltimore, D. (1998) Activation of DNA-
binding activity in an apparently cytoplasmic precursors of the
NF-jB transcription factor. Cell 53, 211–217.
[12] Baeuerle, P.A. and Henkel, T. (1994) Function and activation
of NF-jB in the immune system. Annu. Rev. Immunol. 12,
141–179.
[13] Im, S.Y., Han, S.J., Ko, H.M., Choi, J.H., Chun, S.B., Lee, D.G.,
Ha, T.Y. and Lee, H.K. (1997) Involvement of nuclear factor-jB
in platelet-activating factor-mediated tumor necrosis factor-alpha
expression. Eur. J. Immunol. 27, 2800–2804.
[14] Han, S.J., Choi, J.H., Ko, H.M., Choi, I.W., Lee, H.K., Lee, O.H.
and Im, S.Y. (1999) Glucocorticoids prevent NF-jB activation by
inhibiting the early release of platelet-activating factor in response
to lipopolysaccharide. Eur. J. Immunol. 29, 1334–1341.
[15] Choi, J.H., Ko, H.M., Kim, J.W., Lee, H.K., Han, S.J., Chun,
S.B. and Im, S.Y. (2001) Platelet-activating factor-induced early
activation of NF-jB plays a crucial role for organ clearance of
Candida albicans. J. Immunol. 166, 5139–5144.
[16] Ko, H.M., Seo, K.H., Han, S.J., Ahn, K.Y., Choi, I.H., Koh,
G.Y., Lee, H.K., Ra, M.S. and Im, S.Y. (2002) NF-jB depen-
dency of platelet-activating factor-induced angiogenesis. Cancer
Res. 62, 1809–1814.
[17] Bond, M., Fabunmi, R.P., Baker, A.H. and Newby, A.C. (1998)
Synergistic upregulation of metalloproteinase-9 by growth factors
and inﬂammatory cytokines: an absolute requirement for tran-
scription factor NF-jB. FEBS Lett. 435, 29–34.
[18] Esteve, P.O., Chicoine, E., Robledo, O., Aoudjit, F., Descoteaux,
A., Potworowski, E.F. and St-Pierre, Y. (2002) Protein kinase C-
zeta regulates transcription of the matrix metalloproteinase-9 gene
induced by IL-1 and TNF-ain glioma cells via NF-jB. J. Biol.
Chem. 277, 35150–35155.
[19] Templeton, N.S. and Stetler Stevenson, W.G. (1991) Identiﬁca-
tion of a basal promoter for the human Mr 72000 type IV
collagenase gene. Cancer Res. 51, 6190–6193.
[20] Takahashi, K., Sawasaki, Y., Hata, J., Mukai, K. and Goto, T.
(1990) Spontaneous transformation and immortalization of hu-
man endothelial cells. In Vitro Cell Dev. Biol. 26, 265–274.
[21] Seo, K.H., Ko, H.M., Choi, J.H., Jung, H.H., Chun, Y.H., Choi,
I.W., Lee, H.K. and Im, S.Y. (2004) Essential role for platelet-
activating factor-induced NF-jB activation in macrophage-
derived angiogenesis. Eur. J. Immunol. 34, 2129–2137.
[22] Hughes, S.E. (1996) Functional characterization of the sponta-
neously transformed human umbilical vein endothelial cell line
ECV304: use in an in vitro model of angiogenesis. Exp. Cell Res.
225, 171–185.
[23] Risau, W. (1997) Mechanisms of angiogenesis. Nature 386, 671–
674.
[24] Im, S.Y., Ko, H.M., Kim, J.W., Lee, H.K., Ha, T.Y., Lee, H.B.,
Oh, S.J., Bai, S., Chung, K.C., Lee, Y.B., Kang, H.S. and Chun,
S.B. (1996) Augmentation of tumor metastasis by platelet-
activating factor. Cancer Res. 56, 2662–2665.
H.-M. Ko et al. / FEBS Letters 579 (2005) 2369–2375 2375[25] Camussi, G., Montrucchio, G., Lupia, E., De Martino, A.,
Perona, L., Arese, M., Vercellone, A., Toniolo, A. and Busso-
lino, F. (1995) Platelet-activating factor directly stimulates in
vitro migration of endothelial cells and promotes in vivo
angiogenesis by a heparin-dependent mechanism. J. Immunol.
154, 6492–6501.
[26] Montrucchio, G., Lupia, E., Battaglia, E., Passerini, G.,
Bussolino, F., Emanuelli, G. and Camussi, G. (1994) Tumor
necrosis factor alpha-induced angiogenesis depends on in situ
platelet-activating factor biosynthesis. J. Exp. Med. 180, 377–
382.
[27] Camussi, G., Montrucchio, G., Lupia, E., Soldi, R., Comoglio,
P.M. and Bussolino, F. (1997) Angiogenesis induced in vivo
by hepatocyte growth factor is mediated by platelet-activating
factor synthesis from macrophages. J. Immunol. 158, 1302–
1309.
[28] Bussolino, F., Arese, M., Montrucchio, G., Barra, L., Primo, L.,
Benelli, R., Sanavio, F., Aglietta, M., Ghigo, D., Rola-Pleszczyn-
ski, M.R., Bosia, A., Albini, A. and Camussi, G. (1995) Platelet
activating factor produced in vitro by Kaposis sarcoma cells
induces and sustains in vivo angiogenesis. J. Clin. Invest. 96, 940–
952.
[29] Pitton, C., Lanson, M., Besson, P., Fetissoﬀ, F., Lansac, J.,
Benveniste, J. and Bougnoux, P. (1989) Presence of PAF-acether
in human breast carcinoma: relation to axillary lymph node
metastasis. J. Natl. Cancer Inst. 81, 1298–1302.[30] Montrucchio, G., Sapino, A., Bussolati, B., Ghisolﬁ, G., Rizea-
Savu, S., Silvestro, L., Lupia, E. and Camussi, G. (1989) Potential
angiogenic role of platelet-activating factor in human breast
cancer. Am. J. Pathol. 153, 1589–1596.
[31] Lupia, E., Montrucchio, G., Battaglia, E., Modena, V. and
Camussi, G. (1996) Role of tumor necrosis factor-alpha and
platelet-activating factor in neoangiogenesis induced by synovial
ﬂuids of patients with rheumatoid arthritis. Eur. J. Immunol. 26,
1690–1694.
[32] Okada, S., Kita, H., George, T.J., Gleich, G.J. and Leiferman,
K.M. (1997) Migration of eosinophils through basement mem-
brane components in vitro: role of matrix metalloproteinase-9.
Am. J. Respir. Cell. Mol. Biol. 17, 519–528.
[33] Tao, Y., Bazan, H.E. and Bazan, N.G. (1997) Platelet-activating
factor induces the expression of metalloproteinases-1 and -9, but
not -2 or -3, in the corneal epithelium. Invest. Ophthalmol. Vis.
Sci. 36, 345–354.
[34] Shan, L., Nishimura, Y., Kotani, Y. and Yokoyama, M. (1999)
Platelet-activating factor increases the expression of metallopro-
teinase-9 in human bronchial epithelial cells. Eur. J. Pharmacol.
374, 147–156.
[35] Axelrad, T.W., Deo, D.D., Ottino, P., Kirk, J.V., Bazan, N.G.,
Bazan, H.E.P. and Hunt, J.D. (2004) Platelet-activating factor
(PAF) induces activation of metalloproteinase 2 activity and
vascular endothelial cell invasion and migration. FASEB J. 18,
568–570.
